Prof. Kerry Chester leads the Antibody Engineering Group at the UCL Cancer Institute. She has over twenty years experience in antibody engineering and antibody phage-display technology. Her main research interests are design and construction of antibody-based therapeutics and the interaction of these molecules with specific cancer targets. The work is largely translational; her group designed and manufactured the first single chain Fv antibody (scFv) to enter clinical trials and she is the academic lead of a GMP facility, manufacturing recombinant antibody-based cancer treatments for first-in-human trials. Current projects include bench-to-bedside development of antibodies for use as: cancer imaging agents, antibody drug conjugates, chimeric antigen receptors (CARS) and nano-medicines.
Professor Kerry Chester
UCL Cancer Institute
Paul O’Gorman Building
University College London
72 Huntley Street
London UK
WC1E 6BT
Tel: +44 (0) 20 7679 0700
email: k.chester@ucl.ac.uk
